The ongoing clinical trial at Peking University Third Hospital aims to assess the efficacy and safety of low-dose IL-2 in treating immune-associated ALS syndrome. Given the limited treatment options available for ALS, a successful outcome could position IL-2 as a novel therapeutic approach, potentially capturing a significant share of the ALS treatment market. The trial's focus on immune-mediated variants of ALS, such as multifocal motor neuropathy and Lewis-Sumner syndrome, may also broaden the addressable patient population. Competitive analysis indicates that while several therapies are in development for ALS, few specifically target immune-related mechanisms, which could provide a unique market advantage. Diligence should focus on the trial's recruitment progress and the robustness of safety and efficacy data as it becomes available.